Welcome to our dedicated page for McKesson SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
McKesson Corporation filings document operating results, capital structure, financing arrangements, governance matters, and registered securities for the healthcare services and pharmaceutical distribution company. Its 8-K reports include quarterly and annual results, financial guidance, share repurchase authorizations, dividend-related disclosures, and Regulation FD materials connected to earnings communications.
McKesson's SEC records also cover material credit agreements, including revolving credit facilities and subsidiary senior secured facilities, as well as executive officer transition disclosures and related arrangements. The filing record identifies NYSE-listed common stock and debt securities, including notes due 2026 and 2029, and includes a Form 25 notice for removal from listing and registration of notes due 2025.
McKesson Corporation is asking shareholders to vote at its virtual 2026 Annual Meeting on July 22, 2026. Items include electing 11 directors for one-year terms, ratifying Deloitte & Touche LLP as auditor for fiscal 2027, and approving executive compensation on an advisory basis.
The Board has combined the CEO and Chair roles under Brian S. Tyler and appointed Dominic J. Caruso as Lead Independent Director, while long‑time director Donald R. Knauss will retire under tenure and age limits. Ten of 11 nominees are independent, and 70% of independent nominees have served five years or less.
For fiscal 2026, McKesson reports total revenue of $403 billion, earnings per diluted share of $38.38, adjusted EPS of $39.11, operating profit of $6.4 billion, operating cash flow of $6.2 billion and free cash flow of $5.4 billion, reflecting a 12% revenue increase.
McKesson Corporation reports that certain subsidiaries, including McKesson Medical-Surgical Top Holdings, entered into an amendment to their credit agreement to provide a new $2,250.0 million senior secured Term B loan facility due 2032.
The Term B Loan Facility bears interest at the borrower’s option at either the Adjusted Term SOFR Rate plus 2.25% per year or the Base Rate plus 1.25% per year, with an initial selection of the SOFR-based option. The facility is secured by substantially all tangible and intangible assets of the borrower and certain material U.S. subsidiaries, which act as guarantors.
The credit agreement includes financial covenants, including a maximum total net leverage ratio and a minimum interest coverage ratio, both with customary cure rights. Other terms of the underlying credit agreement remain substantially the same except for changes made by this amendment.
McKesson Corporation’s Chief Executive Officer Brian S. Tyler reported an open-market sale of 4,929 shares of Common Stock at 763.00 per share on June 9, 2026, under a previously adopted Rule 10b5-1(c) trading plan. Following the sale, he directly holds 22,845 shares and has an additional 215.7489 shares held indirectly through the McKesson Corporation 401(k) Retirement Savings Plan.
MCK filing reports proposed sale of Common Stock tied to restricted stock vesting. The notice lists 2,181 shares vesting on 05/21/2026 and 2,748 shares vesting on 05/23/2026, with the broker shown as Fidelity Brokerage Services LLC.
The form is a notification of share disposition under the stock plan following vesting; timing and price of any open‑market sales are not stated in the provided excerpt.
MCKESSON CORP senior vice president, controller and chief accounting officer Napoleon B. Rutledge Jr. reported an open-market sale of 133 shares of common stock at $764 per share. After this Form 4 transaction, he holds 632 shares directly. The sale was executed under a previously adopted Rule 10b5-1(c) trading plan dated March 2, 2026.
McKesson Corporation executive Thomas L. Rodgers reported open-market sales of company stock under a pre-arranged trading plan. He sold 699 shares of common stock at about $735.27 per share on one day and 123 shares at about $735.50 per share on the prior day, for a total of 822 shares sold. After these transactions, he directly holds 2,268 McKesson common shares. The filing notes the sales were made pursuant to a previously adopted Rule 10b5-1(c) plan, indicating the trades were scheduled in advance rather than timed discretionarily.
McKesson Corporation executive LeAnn B. Smith, EVP & Chief HR Officer, sold 1,810 shares of McKesson common stock in an open-market transaction on June 1, 2026 at $735.50 per share. The sale was made under a previously adopted Rule 10b5-1 trading plan dated June 8, 2025, indicating it was pre-scheduled. After this transaction, she directly owns 4,798 shares of McKesson common stock.
Thomas L. Rodgers reported proposed sales of Common Stock under Rule 144. The filing lists restricted stock vesting events of 167, 226, and 306 shares on 05/20/2026, 05/21/2026, and 05/23/2026, respectively. It also records recent sales of 2,388 shares for $1,817,482.92 on 05/26/2026 and 123 shares for $90,466.50 on 06/01/2026.
Cheung Kenny K reported acquisition or exercise transactions in this Form 4 filing.
McKesson Corporation EVP & CFO Kenny K. Cheung reported awards of restricted stock units that provide future rights to common shares as part of his compensation. He received 3,019 RSUs and a separate grant of 8,082 RSUs, each tied to McKesson common stock.
The footnote states these RSUs will vest in three equal installments on June 1, 2027, June 1, 2028, and June 1, 2029, creating a multi-year incentive for continued service and performance. The transactions do not reflect open-market purchases or sales.